Merja H Voutilainen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7100814/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature, 2007, 448, 73-77.	27.8	382
2	Development and plasticity of meningeal lymphatic vessels. Journal of Experimental Medicine, 2017, 214, 3645-3667.	8.5	311
3	Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's Disease. Journal of Neuroscience, 2009, 29, 9651-9659.	3.6	238
4	Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Experimental Neurology, 2011, 228, 99-108.	4.1	118
5	CDNF Protects the Nigrostriatal Dopamine System and Promotes Recovery after MPTP Treatment in Mice. Cell Transplantation, 2012, 21, 1213-1223.	2.5	112
6	Gene therapy with <scp>AAV</scp> 2â€ <scp>CDNF</scp> provides functional benefits in a rat model of <scp>P</scp> arkinson's disease. Brain and Behavior, 2013, 3, 75-88.	2.2	72
7	Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease. FEBS Letters, 2015, 589, 3739-3748.	2.8	71
8	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease, 2020, 10, 875-891.	2.8	63
9	Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra. Journal of Neuroinflammation, 2014, 11, 209.	7.2	56
10	Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action. ENeuro, 2017, 4, ENEURO.0117-16.2017.	1.9	47
11	Characterization of a new lowâ€dose 6â€hydroxydopamine model of Parkinson's disease in rat. Journal of Neuroscience Research, 2016, 94, 318-328.	2.9	39
12	Implementation of deep neural networks to count dopamine neurons in substantia nigra. European Journal of Neuroscience, 2018, 48, 2354-2361.	2.6	38
13	Intrastriatally Infused Exogenous CDNF Is Endocytosed and Retrogradely Transported to Substantia Nigra. ENeuro, 2017, 4, ENEURO.0128-16.2017.	1.9	32
14	Netrinâ€l and its receptor DCC modulate survival and death of dopamine neurons and Parkinson's disease features. EMBO Journal, 2021, 40, e105537.	7.8	32
15	Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease. Neuroscience, 2018, 374, 250-263.	2.3	27
16	Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations inÂvivo. Molecular Therapy, 2021, 29, 2821-2840.	8.2	26
17	Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease. Journal of Neuroscience Research, 2018, 97, 346-361.	2.9	24
18	Glial Cell Line–Derived Neurotrophic Factor Receptor Rearranged During Transfection Agonist Supports Dopamine Neurons <i>In Vitro</i> and Enhances Dopamine Release <i>In Vivo</i> . Movement Disorders, 2020, 35, 245-255.	3.9	24

Merja H Voutilainen

#	Article	IF	CITATIONS
19	Survival and Motor Phenotypes in FVB C9-500 ALS/FTD BAC Transgenic Mice Reproduced by Multiple Labs. Neuron, 2020, 108, 784-796.e3.	8.1	22
20	Double Split Rings as Extremely Small and Tuneable Antennas for Brain Implantable Wireless Medical Microsystems. IEEE Transactions on Antennas and Propagation, 2021, 69, 760-768.	5.1	22
21	Pre-α-pro-GDNF and Pre-β-pro-GDNF Isoforms Are Neuroprotective in the 6-hydroxydopamine Rat Model of Parkinson's Disease. Frontiers in Neurology, 2018, 9, 457.	2.4	21
22	Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Elevates Stimulus-Evoked Release of Dopamine in Freely-Moving Rats. Molecular Neurobiology, 2018, 55, 6755-6768.	4.0	11
23	Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats. Journal of Parkinson's Disease, 2021, 11, 1023-1046.	2.8	8
24	Cerebral Dopamine Neurotrophic Factor Diffuses Around the Brainstem and Does Not Undergo Anterograde Transport After Injection to the Substantia Nigra. Frontiers in Neuroscience, 2019, 13, 590.	2.8	7
25	MANF Is Neuroprotective in Early Stages of EAE, and Elevated in Spinal White Matter by Treatment With Dexamethasone. Frontiers in Cellular Neuroscience, 2021, 15, 640084.	3.7	7
26	GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson's Disease. , 2020, 1, 100004.		1
27	Antennas and Wireless Power Transfer to Small Biomedical Brain Implants. , 2022, , .		1